In this regard, given the relevant role of both the RAS/RAF and AKT/mTOR pathway in HCC, several clinical trials have tested the efficacy of sorafenib in combination with mTOR (mechanistic target of rapamycin) inhibitors. This evidence concerns the gene AKT1 and hepatocellular carcinoma.